A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis,” published in the November 2024 issue of Dermatology by Ferris et al.

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

Exacerbations of the chronic and progressive inflammatory disease bronchiectasis can impact quality of life. Treatment, based ...

Psoriasis is an autoimmune condition that can turn your skin red, and leave you with raised skin lesions, itching and burning ...

Psoriasis is a chronic autoimmune disorder that causes raised areas of dry, itchy, scaly skin. It is not contagious but can cause unsightly and even painful lesions covering large parts of the body in ...

The patient's Psoriasis Area and Severity Index (PASI ... and ustekinumab for 2 years, he persisted with severe lesions in 4 extremities and torso that significantly impacted his quality of life.

Data from patients with high-risk NSTE-ACS further suggest lesion-specific FFR CT provides an enhanced ... the value of HeartFlow ONE including FFR CT Analysis and AI-enabled Plaque Analysis in ...

IL-23 p19 inhibitors elicit clinical response in both bio-naive and bio-exposed patients and show superiority to tumour necrosis factor α inhibitors in plaque psoriasis. Reported differences in ...

Statistically significant improvements were also achieved across all major secondary endpoints, including: 52.9% achieved a Psoriasis Area Severity Index (PASI) 90 response compared to 6.2% of ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...